PR in the Philippines

HONG KONG, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) – TIME Interconnect Technology Limited (“TIME Interconnect”, Stock Code: 1729.HK, with its subsidiaries collectively referred to as the “Group”) , a leading manufacturer of cable assembly, digital cable, and server products, has recently announced its final results for the year ended 31 December 2024 is pleased to announce its final results for the year ended 31 December 2024 (the “Current Year” or “FY2024”). The Group achieved record-breaking growth, driven by strategic expansions in high-margin sectors and excellent execution. During the FY2024, global economic growth experienced a notable slowdown, primarily due to persistently high borrowing costs, the gradual withdrawal of fiscal support, and heightened geo-economic fragmentation. These factors collectively exerted downward pressure on overall market demand. Moreover, cyclical imbalances among major economies began to stabilise, with economic activities gradually returning to potential levels. Amid this challenging macroeconomic landscape, the Group demonstrated agility and resilience by accelerating its business transformation and product upgrades. Notably, it capitalised on the surging demand for server and data centre infrastructure driven by the rapid emergence of artificial intelligence (AI), which remained a key growth engine and contributed to strong revenue performance in the data centre and specialty cable segments. For the Current Year, the Group recorded revenue amounting to HK$7,388.8 million, represented an increase of HK$2562.5 million or 53.1% as compared with HK$4,826.3 million for the Previous Year. Operating profit for the Current Year was HK$623.6 million, represented an increase of HK$190.2 million or 43.9%, as compared with HK$433.4 million for the Previous Year. The operating profit margin dropped slightly from 9.0% to 8.4% for the Current Year, primarily attributable to an increase in research and development expenditure. Net profit of the Current Year was HK$450.5 million, represented an increase of HK$172.9 million or 62.3%, as compared with HK$277.6 million for the Previous Year, with the net profit margin raised from 5.8% to 6.1% for the Current Year*. Basic earnings per share for the Current Year was HK23.2 cents as compared to the basic earnings per share of HK14.2 cents in the Previous Year. Business Review The Group’s turnover by market sector is as follows: Market SectorTurnover (HK$ million) Share of Turnover Year ended 31 December 2024Nine months ended 31 December 2023ChangesYear ended 31 December 2024Nine months ended 31 December 2023Cable assembly Data centre1,213.5 791.0 53.4% 16.4% 16.4% Telecommunication566.8 555.4 2.1% 7.7% 11.5% Medical equipment 816.6 258.0 216.5% 11.1% 5.3% Industrial equipment 29.2 24.4 19.7% 0.4% 0.5% Automotive 157.7 100.4 57.1% 2.1% 2.1% Digital cable  Networking cable 1,179.9 788.7 49.6% 16.0% 16.4% Specialty cable 237.0 77.0 207.8% 3.2% 1.6% Server 3,188.1 2,231.4 42.9% 43.1% 46.2% Total 7,388.8 4,826.3 53.1% 100% 100% Data centre sectorThe revenue of the data centre segment increased by HK$422.5 million to HK$1,213.5 million for the Current Year as compared to HK$791.0 million for the Previous Year. Benefiting from the surge in artificial intelligence and server upgrades, shipment levels remained strong during the FY2024, and the sector remained to be the highest revenue contributor in the cable assembly business. Telecommunication sectorRevenue from the telecommunication sector rose by HK$11.4 million to HK$566.8 million for the Current Year, compared to HK$555.4 million in the Previous Year. Although part of the production capacity has been shifted to data centre sector due to its order volume increased. But better margin orders of telecommunication sector have been retained to improve the product portfolio of overall cable assembly business. Medical equipment sectorDuring the Current Year, the Group paid more attention and efforts in the medical equipment cables business and continued to enhance its medical equipment customers base, as well as to strengthen its R&D capabilities. Benefited from the setup of two new plants last year, Time Kunshan and Time Jiangxi, and expanded production capacity and R&D capabilities for medical equipment cables products, the revenue of the medical equipment sector for the Current Year significantly increased to HK$816.6 million, representing a substantial rise of HK$558.6 million compared to HK$258.0 million for the Previous Year. The Group continued to increase investment in this sector, enhancing both production capacity and R&D capabilities. The Group expects that, with growing health awareness, demand for medical equipment will continue to rise. Industrial equipment sectorDespite the underperforming global economic recovery, and the pressures from high inflation and interest rates on economic activities, the revenue of the industrial equipment sector increased. The revenue rose from HK$24.4 million in the Previous Year to HK$29.2 million for the FY2024, representing an increase of 19.7%. Automotive sectorDespite the ongoing impact of geopolitics and the trade war, sales orders for automotive wire harness products remained at a relatively low level. However, the revenue of the automotive sector increased to HK$157.7 million for the Current Year, up by HK$57.3 million from HK$100.4 million in the Previous Year.  The Group still believes that the automotive wiring products can help the Group to provide its customers with a broader product portfolio, and to step into a new business sector by enriching the Group’s business portfolio and broadening its unique customer base, which can capture opportunities brought by the booming electric vehicle market. Additionally, the Group established a wholly-owned subsidiary, Linkz Cables Mexico S. de R.L. de C.V. ("Linkz Mexico"), in Mexico, aiming to increase its market share outside China and Asia. Networking cable sectorEven a lot of negative factors, such as the divergences between countries, war, high interest rates, strong US dollar and high inflation, were remained exist, during the FY2024, overseas orders for the networking cable sector continued to improve, with revenue rising to HK$1,179.9 million, an increase of HK$391.2 million from HK$788.7 million in the Previous Year. The increase in copper prices reflects ongoing growth in market demand. Furthermore, the establishment of Linkz Mexico has helped enhance the Group's market share in the United States and Mexico. Specialty cable sectorDriven by the surge in demand for high-speed cables fuelled by artificial intelligence applications, the specialty cable sector experienced robust growth. Revenue for the sector increased significantly to HK$237.0 million for the FY2024, up by HK$160.0 million or 207.8% compared to HK$77.0 million in the Previous Year. The growth in high-speed cables also contributed to improved profit margins, further enhancing the Group's overall profitability. Server sectorDuring the Current Year, the revenue of the server sector grew significantly to HK$3,188.1 million, an increase of HK$956.7 million compared to HK$2,231.4 million in the Previous Year. Despite challenges in the first half of the year due to shortages in key component supplies, the Group worked very hard to find all the business solutions to cope with this situation. Finally, the supply of these key components has been resolved and the production has been resumed immediately, leading to a strong recovery in the second half. Continued strong demand for servers further drove business growth. ProspectDespite challenges in the macroeconomic environment, including global growth uncertainties and geopolitical tensions, the Group’s management remains confident in its future business development. Looking ahead, the Group will continue to embrace flexibility and continuous innovation, focusing on strengthening supply chain resilience, expanding international presence, and driving diversified business growth to ensure long-term development. In the FY2024, the Group has proactively expanded its overseas business with the establishment of Linkz Mexico, a wholly-owned subsidiary. The new factory is expected to commence full production within the year, primarily manufacturing digital cables and automotive wire harness products. This aligns with the "China-Plus-One" strategy, mitigating geopolitical risks and ensuring export stability. With the rapid growth in demand for electric vehicles, automotive wire harness products have become a key driver for the Group’s next phase of growth. Meanwhile, the acceleration of global 5G deployment, along with the normalisation of remote work and cloud applications, will continue to propel the Group’s growth in telecommunications cables and server solutions. In the server segment, the Group has successfully expanded its data centre product line through its JDM/ODM business model, continuously customising solutions to meet the needs of brand clients. Riding on the PRC government’s “channelling computing resources from the eastern areas to the western regions” initiative and leveraging Luxshare Group’s technological platform and market resources, the Group will further scale its data centre business and seize the significant market opportunities arising from the rapid advancement of artificial intelligence, big data, and cloud computing. In the medical technology sector, Dr. Cua Tin Yin Simon, the Group’s CEO, remains optimistic about the prospects， “In 2024, the Group further increased its investments, including a stake in a Japanese medical and healthcare company with a proven operational history of over 30 years. In addition, the Group invested in a UK-based startup with seven years of professional experience in haptics and virtual reality. This company has developed innovative wearable haptic technology capable of simulating weight, resistance, and assistive forces in virtual environments. With initial applications in digital health and fitness within the spatial computing space, the technology merges wellness, fitness, and gaming to optimise human performance—targeting the vast markets of gaming and neuromuscular rehabilitation. The Group believes that these strategic investments will allow it to leverage the companies’ technological expertise and create synergy in developing medical-related products, particularly in R&D, manufacturing, and global market expansion. In line with our expansion strategy, two new liaison offices—Time US and Time UK—have also been established to deepen our global business presence.” Additionally, in 2024, Dr. Cua facilitated the establishment of the Medical Engineering and Innovation Council under the Federation of Hong Kong Industries (FHKI), where he serves as Co-Chair alongside Chuang Tzu Hsiung, Chairman of both FHKI and the Hong Kong New Industrialisation Development Alliance. The council is dedicated to establish a medical engineering frontier tracking mechanism to deeply explore technology transformation and commercialization potential. Secondly, it constructs an integrated "Government-Industry-University-Research-Investment" collaborative platform, consolidating government policies, university R&D, clinical resources, and industrial capital. By establishing joint laboratories and rapid conversion channels, it accelerates the commercialization of scientific research outcomes. Simultaneously, the council strengthens cross-border cooperation by connecting global innovation networks, introducing international certification bodies and technology transfer platforms, assisting Hong Kong enterprises in overcoming overseas market access barriers, and establishing cross-border industry-university-research bases to reinforce the region's innovation hub status. Finally, it implements a full-cycle industry cultivation program, providing comprehensive support for start-ups from prototype development, regulatory certification, clinical trials to mass production. While promoting traditional industry transformation and global market expansion, it facilitates the formation of a complete ecosystem for Hong Kong's medical technology industry - "Research & Development - Conversion - Industrialization" - to address global health challenges and enhance international competitiveness. The Group believes that, while pursuing business growth, it is also essential to fulfill its corporate social responsibility by actively addressing social issues such as health, innovation, and industry upgrading. Moving forward, the Group will focus on high-potential areas, leveraging innovation, collaboration, and sustainability to strengthen its core competitiveness and position itself as a leading provider of network solutions and medical technology infrastructure, creating greater value for shareholders and society. Key Milestone - Establishment of the Medical Engineering and Innovation Council About TIME Interconnect Technology Limited TIME Interconnect Technology Limited is a well-established supplier of customised interconnect solutions with over 30 years’ experience in the industry. The Group is headquartered in Hong Kong, and has manufacturing facilities in Shanghai, Suzhou, Jiangxi and Huizhou, the People’s Republic of China (“PRC”), Japan and Mexico. The Group currently manufactures and supplies a wide variety of copper & optical fiber cable assemblies, digital cable products and servers which are produced to the specifications and designs of its individual customer partners. Its products are used by a number of established PRC and international customers in a variety of market sectors, including telecommunication, data centre, industrial equipment, medical equipment, automotive wire harness, digital cable and server. This press release is disseminated by Bright Communications International Limited on behalf of TIME Interconnect Technology Limited. For further enquiries, please contact Bright Communications International Limited: Ms. Ashley KungTel: (852) 46371627Mob: (852) 6608 9927Email:ashley.kung@brightcommns.com*Note: The financial year end date of the Company has been changed from 31 March to 31 December in July 2023. For details, please refer to the Company’s announcement dated 24 July 2023. In view of this change, the consolidated financial statements of the Group cover the twelve-month period from 1 January 2024 to 31 December 2024 and the comparative figures cover the nine-month period from 1 April 2023 to 31 December 2023. It should be noted that the financial data presented herein are being compared with that for the nine-month period ended 31 December 2023. The difference in duration of the two financial periods should be considered when making year-on-year comparisons. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) - The Board of Directors (“Board”) of Mooreast Holdings Ltd. (“Mooreast” or the “Company”), and together with its subsidiaries, the “Group”) wishes to provide an update on several recent developments: Completion of Multi-Buoy Mooring Upgrade Project at Gulf of ThailandFurther to the Company’s announcement dated 12 November 2024, Mooreast wishes to update that the project to upgrade a multi-buoy mooring (“MBM”) system off the eastern shore of the Gulf of Thailand was completed recently. The Group expects to recognise approximately S$8.8 million for this project in the first half of the financial year ending 31 December 2025 (“1H2025”).The successful completion underscores the Group’s capabilities to handle sizeable mooring projects within the oil and gas (“O&G”) industry. Orders related to the O&G sector had been building up in 2H2024, and have continued to gain momentum in the first four months of FY2025. Even with the delivery of the MBM project, current orders at hand are at least equal to those at the end of FY2024. Accordingly, the Group expects revenue in 1H2025 to exceed the S$13.7 million recorded in 1H2024.       Additionally, the Group does not expect that the administrative and other operating expenses to increase significantly in FY2025 given that the current staffing is sufficient to support operations and business development in the near term and the absence of fees for professional services rendered to support the Group’s business repositioning efforts in FY2024. Management is actively reviewing and implementing cost control measures to improve overall cost efficiency and profitability moving forward.Update on Floating Wind Energy Projects in Europe and North AsiaOn 1 January 2025, Mr. Eirik Ellingsen (“Mr. Ellingsen”), a Norwegian with deep experience in the offshore and marine sector, was appointed Chief Executive Officer (“CEO”). In the last four months, he has been working closely with Mr. Sim Koon Lam (“Mr Sim”), the founder, Executive Director and Deputy Chairman, on business development strategies amid an increase in commercialisation of floating wind energy projects worldwide.Mr. Ellingsen has been actively engaging players involved in floating wind energy projects in Europe and North Asia, and participated in the WindEurope conference in Copenhagen, Denmark, earlier this month. While the ‘first wave’ of implementation – involving largely demonstration and precommercial projects – had been delayed by the supply chain disruptions caused by the COVID-19 pandemic, the industry has clearly advanced to the ‘second wave’ – commercialisation at scale. With the progress toward commercialisation, the Environmental Resources Management’s “Q3 2024 Global Offshore Wind Market Update" reported over 390 GW of floating wind projects in various planning and development stages. Compared to 50-100 megawatts (“MW”) typical at pre-commercialisation, the latter involves projects of at least 500 MW each. Many of these projects are reaching the final investment decision (“FID”) phase in 2026 and 2027. These include multigigawatt (“GW”) scale projects which can contribute substantially to the growth of offshore wind capacity globally. Typically, mooring and rigging solutions, including anchors, chains, and ropes, account for between 5% to 10% of the total value of each floating wind energy project.           Approximately 5.5 GW of floating wind capacity is expected to reach FID in the next 24-36 months. Of this, about two-thirds involve projects in Europe, including those in the North Sea, while a third will come from North Asia. These projects may be deemed as the addressable market of Mooreast. As the Group is currently not targeting U.S. floating wind energy projects, it is not subject to U.S. Government tariffs for its products. Already, Mooreast is working closely with these projects and has indicated its component costings. As these progress to full implementation, developers and partners are looking for a reliable manufacturer capable of handling the large volumes of anchors and mooring components required for these large-scale projects. The Group believes it is uniquely positioned, given its status as Asia’s only ultra-high power anchor designer and manufacturer and its global footprint. Mooreast recently opened new offices in Taiwan and Malaysia in June and July 2024, respectively, expanding its presence in the Asian region.The Group continues to assess the ability of its present facility at 51 Shipyard Road in Singapore to handle production of anchors and components as these projects advance to formal tender, noting that developers have indicated suppliers would need to demonstrate beforehand sufficient capacity to handle the indicative volume. Should such orders escalate beyond the current capacity of the existing yard, Mooreast would need to explore access to additional capacity. Meanwhile, the Company continues to develop its supply chain to better serve its customers globally. The Company will provide updates to shareholders as and when there are material developments regarding floating renewable energy projects. BY ORDER OF THE BOARD MOOREAST HOLDINGS LTD.Mr Eirik Ellingsen Chief Executive Officer23 April 2025This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.  The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. The presentations include post-hoc analyses of two Phase 2 clinical studies of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, being developed for treatment of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM). A third presentation will present preclinical results for rimtoregtide (HTD4010), a peptide derived from the Reg3a protein, in liver failure in mice.“Effects of Berberine Ursodeoxycholate (HTD1801) in Patients with At-risk MASH and T2DM”(Presentation SAT-440, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: Due to the ongoing unmet medical need, clinical development in MASH focuses on patients who are at a higher risk of disease progression and outcomes due to the presence of moderate to advanced fibrosis (defined as at-risk MASH). The purpose of this analysis was to assess the effects of HTD1801 in patients with at-risk MASH and T2DM as defined by baseline MRI cT1 >875 ms. Eighteen weeks of treatment with HTD1801 resulted in substantial improvements in key hepatic and cardiometabolic parameters in patients with at-risk MASH and compared to placebo, twice as many patients achieved a reduction in liver fat content (MRI-PDFF) or fibroinflammation (cT1) that have been associated with improvements in liver histology. These data are particularly insightful as HTD1801 continues to be evaluated in an ongoing paired biopsy study of patients with at-risk MASH and pre-diabetes or diabetes.“Effects of Berberine Ursodeoxycholate (HTD1801) in Chinese Patients with T2DM and Presumed MASLD”(Presentation SAT-432, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: T2DM typically coexists with other metabolic abnormalities such as hyperlipidemia, obesity, and MASH that can exacerbate T2DM and can lead to a worse prognosis with increased risk for mortality and cardiovascular outcomes. In a Phase 2 study in patients with T2DM, HTD1801 achieved the primary endpoint with a significant decrease in HbA1c. Based on the latest diagnostic criteria, it is likely that a substantial subgroup of the study may have had concurrent metabolic dysfunction-associated steatotic liver disease (MASLD). The purpose of this analysis was to evaluate the benefits of HTD1801 in patients with T2DM and MASLD identified by baseline controlled attenuation parameter values >288 dB/M (correlated to 5% liver fat content). HTD1801 treatment demonstrated both dose-dependent improvements in cardiometabolic and hepatic parameters in patients with T2DM and MASLD. These data suggest HTD1801 can comprehensively address metabolic and cardiovascular risk factors beyond glycemic control.“A Comparison of the Protective Effects of Rimtoregtide (HTD4010) and DUR-928 on Acute Liver Failure in Mice”(Presentation FRI-141, Poster Presentation, May 9, 8:30 AM CET)About the Abstract: The purpose of this study was 1) to test the potential protective effects of HTD4010 in an LPS-induced model mimicking acute liver failure in mice and 2) compare these effects to DUR-928, which is currently in late-stage development for the treatment of alcohol-associated hepatitis. In an LPS-induced mouse model mimicking acute liver failure, HTD4010 resulted in significant improvement in survival rates (greater than 2-fold) compared to the model control.  These protective effects of HTD4010 were significantly greater than DUR-928.  These findings provide evidence that HTD4010 may have a beneficial effect on acute liver conditions including alcohol-associated hepatitis and other acute-inflammatory-related conditions.About Berberine UrsodeoxycholateBerberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with a unique dual mechanism of action: AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in insulin resistance, glucose metabolism, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases. HTD1801 is being developed for multiple indications. HTD1801 met the primary endpoint in two Phase 3 clinical trials in patients with type 2 diabetes mellitus (T2DM), demonstrating a clinically meaningful effect on HbA1c. In both trials, key secondary endpoints were achieved, suggesting multiple advantages of HTD1801 including improvement in cardiometabolic risk indicators. In addition to T2DM, HTD1801 efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) has been demonstrated in a Phase 2a clinical trial, and a global multicenter Phase 2b trial assessing the histologic benefit of HTD1801 is currently ongoing, with topline results expected in 2025.About RimtoregtideRimtoregtide (HTD4010) is a clinical-stage compound in development for acute inflammatory-related indications including alcoholic hepatitis (AH). It is a peptide derived from the Reg3a protein with immunomodulatory, anti-inflammatory, and anti-apoptotic effects. HTD4010 has been evaluated in animal models of acute pancreatitis and acute liver failure, where protective effects were observed. A completed Phase 1 clinical trial of HTD4010 in healthy subjects demonstrated a favorable safety profile. AH is caused by chronic heavy alcohol abuse or a sudden, drastic increase in alcohol consumption. It is characterized by severe inflammation and, ultimately, liver failure and death. There is currently no approved treatment for AH and only a few drug candidates are in clinical development. The current standard of care focuses on symptom management, including abstinence, treating inflammation and providing nutrition.About HighTide TherapeuticsHighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across metabolic diseases with significant unmet medical needs. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials including therapies for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), HighTide’s lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.For more information, please visit www.hightidetx.comContact: pr@hightidetx.com Copyright 2025 ACN Newswire via SeaPRwire.com.

JAKARTA, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - South East Asia’s first premium service airline, PT TransNusa Aviation Mandiri, is further strengthening its presence in Singapore by increasing the frequency of its scheduled flights for the Jakarta – Singapore route to two times daily from today.This announcement comes barely a month after TransNusa successfully launch scheduled flights to Perth from its base in Bali.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said that TransNusa has plans to further strengthen its network connectivity this year.In line with this, TransNusa launched its second daily flight to Singapore today. The additional flight, 8B 153, departed at 12.10pm from the Terminal 3 Soekarno – Hatta International Airport and arrived Singapore Changi Airport at 14.40pm today. While its additional flight, 8B 154, departed Changi Airport at 15.30pm and arrived at the Soekarno – Hatta International Airport at 16.20pm.“TransNusa will continue to operate the current scheduled flight, 8B 151, which depart Soekarno – Hatta International Airport at 07.55am and arrive at 10.45am at the Changi Airport,” Datuk Bernard said, adding that the current flight, 8B 152, depart Changi Airport at 11.45am and arrive in Jakarta at 12.30pm.TransNusa has been consistently achieving milestones since the introduction of a new top management led by aviation veteran, Datuk Bernard Francis. The airline, which introduced its first international flight on April 14, 2023, has expanding its wings from South East Asia to the Asia Pacific region within a short span of 2 years.Datuk Bernard attributes the airline’s successes and accelerated growth within the last 24 months to their customised business model and the vastly experienced management team.Datuk Bernard stressed that for its international flights, TransNusa not only provide premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our passengers will enjoy check-in baggage of between 20kgs to 30 kgs, depending on the product purchased,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we provide more complete services such as free baggage 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the ability to be able to change their flight schedule without restrictions and obtain refund when needed.”TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” said Datuk Bernard, adding that the ticket price for the Jakarta – Singapore route starts from as low as SGD52 (USD40).DATUK BERNARD FRANCIS… TransNusa to focus on strengthening network connectivityTransNusa, A Short HistoryTransNusa, which had to close it business operation in September 2020 due to impact of the Covid-19 pandemic on the aviation industry, started operations again after injection of new shareholders and a new management team led by aviation expert, Datuk Bernard, in October 2022.Within 6 months, the airline introduced its first international route between Jakarta and Kuala Lumpur and celebrated its first-year anniversary for this route on April 14, 2024.“When we re-launched TransNusa in October 2022, we started from the bottom again. Everything was new because the pandemic had disrupted the aviation business operations boundaries. As such we re-created and customised our business operations and strategy model of being the first Premium Service Carrier based on the post-pandemic scenario,” Datuk Bernard explained.TransNusa launched its first international route between Jakarta and Kuala Lumpur in April, 2023, followed by the Jakarta – Singapore route on November 20, 2023. After which, the airline successfully launched three more new international routes by the end of 2023. TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to experience strategic growth in the last two years.Since the takeover of new shareholders and the injection of a new management team, TransNusa has been making headlines in Malaysia, Singapore, China and Australia with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China.About TransNusaEstablished in 2005, TransNusa started its operation by providing chartered flights. It began its commercial flights in 2011. After ceasing operations due to the Covid-19 pandemic, TransNusa relaunched itself in 2021 as a low-cost airline in its domestic market. In 2023, TransNusa introduced a new business model making it the first Premium Service Airline in the region. The new business model will apply only to its international routes. TransNusa introduced its first international route in April this year. The airline introduced its Jakarta – Kuala Lumpur round trip route and had its maiden flight on April 14. The airline is currently based in Jakarta Soekarno-Hatta International Airport.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719.Media ContactTrina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

- Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and suppressive function of Tregs compared to baseline values. - Clinically, patients with Frontotemporal Dementia (FTD) demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, no serious adverse events were reported, and all 5 patients completed the study.Houston, TX, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. The study aims to enroll up to 10 patients, and these interim results include data from the first 5 patients with mild to moderate FTD who have completed the full course of treatment.Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: “The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study of patients with ALS treated with low-dose IL-2/CTLA4-Ig.  This interim data in FTD provides us further confidence of our approach to target and enhance Treg biology to address devastating neurodegenerative diseases including ALS and FTD”.Previous biomarker data presented by the Company demonstrated that FTD patients exhibit a compromised immunosuppressive function of regulatory T cells (Tregs), along with increased peripheral levels of inflammatory cytokines and chemokines, dysregulation of monocytes, and systemic activation of the inflammatory cascade, supporting the critical role of the immune system in the pathophysiology of FTD.One previous study showed that a cohort of 68 patients with FTD worsened by an average of 3.57 points over a 12-month period per the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale (Knopman et al. Brain 2008; 131(11): 2957-2968). In addition, patients with FTD typically have shorter survival times and more rapid rates of cognitive and functional decline compared to patients with Alzheimer’s disease (Rascovsky et al. Neurology 2005; 65(3): 397-403).Dr. Fred Grossman, Coya’s Chief Medical Officer stated: “We are excited with the results observed in this initial group of patients with this proof-of-concept study.  We believe that the increase in Treg numbers and suppressive function, with subsequent anti-inflammatory biological activity still to be evaluated, underscores the potential for this low-dose IL-2/CTLA4-Ig combination to be further studied as a therapy for FTD, for which there are no currently approved treatments.”Summary of Interim Study Results      Overall, treatment with low-dose IL-2 and CTLA4-Ig was well tolerated.  All 5 patients enrolled in the first cohort completed the study and received the investigational treatment as planned.  The most common adverse events were mild injection site reactions. No serious adverse events were reported.Treg numbers and suppressive function increased after the first treatment cycle (p < 0.01 and p < 0.05, respectively, and remained at higher significant levels throughout the treatment period.Clinical functional assessments were performed in all patients at pre-specified timepoints over the course of the study using validated tools, including the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale, the Montreal Cognitive Assessment (MoCA) scale, and the Progressive Aphasia Severity Scale (PASS).  Results of the functional tests show that, on average, these five FTD patients treated with low-dose IL-2 and CTLA4-Ig combination exhibited minimal to no cognitive decline over the course of the study, compared to pre-treatment values.The Company intends to publish and/or present more comprehensive data in a future peer-reviewed meeting and/or publication.About Frontotemporal DementiaFrontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized by altered behavior and language, with a progressive decline in executive function.1 FTD affects an estimated 30,000 Americans.2 FTD is categorized clinically into various subtypes; the main three include behavioral-variant frontotemporal dementia and two language variants, semantic dementia (also known as semantic variant primary progressive aphasia) and progressive non-fluent aphasia (also known as non-fluent variant primary progressive aphasia).  It's a presenile dementia, meaning it can occur in younger individuals, often between the ages of 45 and 64. The average age of onset is 58, with an average survival time of 7.5 years.1,2References1. Knopman et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008; 131(11): 2957-29682. Rascovsky et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65(3): 397-403About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.COYA 302 is a combination treatment comprised of low-dose IL-2 and CTLA4-Ig is an investigational therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of Tregs and suppress the inflammation produced by activated monocytes and macrophages. Coya is developing COYA 302 for the treatment of fatal neurogenerative diseases characterized by chronic inflammation and Treg dysfunction.For more information about Coya, please visit www.coyatherapeutics.com Forward-Looking StatementsThis press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact:David Snyder, CFOdavid@coyatherapeutics.com CORE IRBret Shapirobrets@coreir.com 561-479-8566Media ContactsFor Coya Therapeutics:Kati Waldenburgmedia@coyatherapeutics.com212-655-0924 Copyright 2025 ACN Newswire via SeaPRwire.com.